8-Methylquinazolin-4(3H)-One PARP Inhibitors for H-Y-Φ Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of potent, membrane-permeable inhibitors that can selectively target H-Y-Φ PARPs, as most existing inhibitors cannot distinguish between H-Y-E and H-Y-Φ PARPs, leading to a poor understanding of the cellular role of mono-ADP-ribosylation.
Innovation Solution
Development of compounds of specific formulas (I-VII) or their pharmaceutically acceptable salts, which are designed to selectively inhibit H-Y-Φ PARPs by incorporating specific alkyl, alkenyl, or alkynyl groups and aromatic or heterocyclic substitutions, allowing for targeted modulation of PARP activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PARP inhibitors are used, then PARP inhibition activity is achieved, but selectivity between H-Y-E and H-Y-Φ PARPs is lost
Solution Approach 1:
The patent applies local quality by introducing specific structural features at particular positions of the inhibitor molecule. The core structure is modified with specific substituents at defined positions to create regions with distinct chemical properties that preferentially interact with H-Y-Φ PARPs, thereby achieving selectivity while maintaining inhibition activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the inhibitor molecules, including substituent types, positions, and configurations. By optimizing these parameters, the compounds achieve enhanced selectivity for H-Y-Φ PARPs over H-Y-E PARPs while preserving potent inhibition activity.
2Measurement precision
If selective H-Y-Φ PARP inhibitors are developed, then selectivity is improved, but membrane permeability is reduced
Solution Approach 1:
The patent optimizes membrane permeability by carefully selecting and positioning lipophilic substituents. The structural parameters are tuned to achieve the right balance between hydrophobicity for membrane crossing and hydrophilicity for solubility, ensuring that selective inhibitors can effectively reach their intracellular targets.
Solution Approach 2:
The patent creates composite molecular structures that combine polar and non-polar regions. These composite structures contain both hydrophobic aromatic rings for membrane permeation and polar functional groups for selective binding, achieving a balance between permeability and selectivity.
3Strength
If potent inhibitors are designed, then inhibition strength is increased, but cellular role understanding remains poor due to lack of selective tools
Solution Approach 1:
The patent introduces specific local structural features that confer selectivity for H-Y-Φ PARPs. These localized modifications allow potent inhibition while providing the selectivity needed to study the specific cellular roles of mono-ADP-ribosylation without confounding effects from poly-ADP-ribosylation pathways.
Data Source
AI summary
Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.